» Articles » PMID: 37410163

Non-Alcoholic Fatty Liver Disease (NAFLD) and Risk of New-onset Heart Failure: a Retrospective Analysis of 173,966 Patients

Overview
Date 2023 Jul 6
PMID 37410163
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) represents the leading cause of chronic liver disease. Its high mortality and morbidity are mainly caused by non-hepatic comorbidities and their clinical complications. Accumulating evidence suggests an association between NAFLD and heart failure (HF), but large-scale data analyses from Germany are scarce.

Methods: Using the Disease Analyzer database (IQVIA), this analysis retrospectively evaluated two cohorts of outpatients with and without NAFLD with respect to the cumulative incidence of HF as the primary outcome between January 2005 and December 2020. Cohorts were propensity score matched for sex, age, index year, yearly consultation frequency, and known risk factors for HF.

Results: A total of 173,966 patients were included in the analysis. Within 10 years of the index date, 13.2% vs. 10.0% of patients with and without NAFLD were newly diagnosed with HF (p < 0.001). This finding was supported by univariate Cox regression analysis in which NAFLD was found to be significantly associated with subsequent HF (Hazard Ratio (HR) 1.34, 95% Confidence Interval (CI) 1.28-1.39, p < 0.001). The association between NAFLD and HF was observed across all analysed age groups and as comparable between both men (HR 1.30, 95% CI 1.23-1.38; p < 0.001) and women (HR: 1.37, 95% CI 1.29-1.45; p < 0.001).

Conclusion: NAFLD is significantly associated with an increased cumulative incidence of HF, which, given its rapidly increasing global prevalence, could be crucial to further reduce its high mortality and morbidity. We recommend risk stratification within a multidisciplinary approach for NAFLD patients, including systematic prevention or early detection strategies for HF.

Citing Articles

Association of liver fibrosis scores with all-cause and cardiovascular mortality in patients with heart failure.

Guo Z, Ye Z, Xu Q, Li Y, Zheng J Clin Transl Sci. 2024; 17(12):e70104.

PMID: 39686669 PMC: 11649953. DOI: 10.1111/cts.70104.


Aortic regurgitation is associated with African American and Asian race, smoking, renal disease, and numerous autoimmune diseases in addition to traditional cardiovascular risk factors but has lower risk with alcohol intake.

Timmerman B, Hashemzadeh M, Movahed M Clin Res Cardiol. 2024; .

PMID: 38478089 DOI: 10.1007/s00392-024-02424-3.

References
1.
Lan Y, Lu Y, Li J, Hu S, Chen S, Wang Y . Outcomes of subjects who are lean, overweight or obese with nonalcoholic fatty liver disease: A cohort study in China. Hepatol Commun. 2022; 6(12):3393-3405. PMC: 9701482. DOI: 10.1002/hep4.2081. View

2.
Eslam M, Newsome P, Sarin S, Anstee Q, Targher G, Romero-Gomez M . A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020; 73(1):202-209. DOI: 10.1016/j.jhep.2020.03.039. View

3.
Estes C, Anstee Q, Arias-Loste M, Bantel H, Bellentani S, Caballeria J . Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol. 2018; 69(4):896-904. DOI: 10.1016/j.jhep.2018.05.036. View

4.
Huber Y, Boyle M, Hallsworth K, Tiniakos D, Straub B, Labenz C . Health-related Quality of Life in Nonalcoholic Fatty Liver Disease Associates With Hepatic Inflammation. Clin Gastroenterol Hepatol. 2018; 17(10):2085-2092.e1. DOI: 10.1016/j.cgh.2018.12.016. View

5.
Younossi Z, Tacke F, Arrese M, Sharma B, Mostafa I, Bugianesi E . Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology. 2018; 69(6):2672-2682. DOI: 10.1002/hep.30251. View